FDA offers several programmes that encourage and speed up development of treatments for rare or serious conditions. They differ in criteria and benefits, and a single product can hold more than one.
Free sandbox · No credit card · 21 CFR Part 11 aligned
| Orphan | Fast track | Breakthrough | |
|---|---|---|---|
| Rare disease required | |||
| Serious condition required | |||
| Clinical evidence needed | |||
| Rolling review | |||
| Market exclusivity | 7 years |
Compared
| Programme | Criteria | Main benefits |
|---|---|---|
| Orphan drug designation | Intended for a disease affecting fewer than 200,000 people in the US (or with no reasonable expectation of recovering costs) | Tax credits for qualified clinical testing, exemption from certain user fees, 7 years of market exclusivity on approval |
| Fast track | Serious condition and potential to address an unmet medical need, shown by nonclinical or clinical data | More frequent FDA meetings and communication, rolling review of the application |
| Breakthrough therapy | Serious condition and preliminary clinical evidence of substantial improvement over available therapy on a clinically significant endpoint | All fast track features plus intensive guidance from early development and organisational commitment |
| Priority review | Significant improvement in safety or effectiveness for a serious condition | FDA goal to act on the application in 6 months instead of 10 |
| Accelerated approval | Serious condition, meaningful advantage, and an effect on a surrogate or intermediate endpoint reasonably likely to predict benefit | Earlier approval, with confirmatory trials required |
In short
Explained
Designations change the pace and the conversation with regulators more than the mechanics of the trial. Breakthrough therapy in particular brings frequent interaction and can compress timelines between phases, which puts pressure on study start-up and database build. Rolling review means parts of the application are submitted as they are ready, so data management needs to reach clean, lockable data sooner.
For rare disease sponsors, orphan designation often sits alongside natural history studies and small, long trials. See EDC for rare disease trials and the FDA single pivotal trial guidance explainer for related evidence expectations.
Fast track needs potential to address an unmet need in a serious condition; breakthrough needs preliminary clinical evidence of substantial improvement over available therapy, and adds more intensive FDA guidance.
Tax credits for qualified clinical testing, exemption from certain user fees and seven years of US market exclusivity on approval.
Yes. For example, an orphan drug can also have breakthrough therapy designation and priority review.
Yes. The EU has orphan designation and the PRIME scheme for priority medicines.
Build studies from protocols in minutes. Free sandbox.